Skip to content

Stool transplant for treatment of colitis and crohns disease

Role of Faecal Microbiota Transplantation (FMT) in Inflammatory Bowel Disease

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/03/032131
Enrollment
200
Registered
2021-03-18
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K50- Crohns disease [regional enteritis] Health Condition 2: K51- Ulcerative colitis

Interventions

Intervention1: Fecal Microbiota Transplantation: A freshly collected sample will be inspected visually and formed stools (Bristol stool scale, 3 and 4) with no obvious blood or mucous will be accepted
Seward Ltd, Worthing, UK) till it reaches a liquid consistency. Universal precautions will be observed and separate disposable bags will be used for each patient. The particulate matter will be filter

Sponsors

Dayanand Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with IBD aged � 18 years at the time of enrolment Written informed consent to participate

Exclusion criteria

Exclusion criteria: Age Pregnancy Known HIV positive. Disseminated or advanced malignancy. Concomitant severe underlying systemic illness that in the opinion of the investigator would interfere with completion of follow-up. Active drug use or dependence that, in the opinion of the study investigator, would interfere with adherence to study requirements. Any other condition, which in the opinion of the investigator would impede compliance or hinder completion of study. Inability to provide informed consent.

Design outcomes

Primary

MeasureTime frame
To study the efficacy of faecal microbiota transplantation (FMT) in ulcerative colitis To study the efficacy of faecal microbiota transplantation (FMT) in Crohn�s disease Timepoint: 4 weeks, 12 weeks, 24 weeks, 52 weeks

Secondary

MeasureTime frame
To study the efficacy and safety of FMT in pouchitis and extra-intestinal manifestations of IBD.Timepoint: 4 weeks, 12 weeks, 24 weeks, 52 weeks;To study the microbiota profile of the donors and FMT recipients pre and post FMT and compare with the donor microbiota profileTimepoint: 4 weeks, 12 weeks, 24 weeks, 52 weeks;To study the safety of FMT in ulcerative colitis and crohn�s disease Timepoint: 4 weeks, 12 weeks, 24 weeks, 52 weeks

Countries

India

Contacts

Public ContactAjit Sood

Department of Gastroenterology Third Floor Dayanand Medical College and Hospital Ludhiana

ajitsood10@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026